SAN DIEGO, July 08, 2025--(BUSINESS WIRE)--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, ...

SAN DIEGO, CA--(Marketwired - Feb 10, 2016) - Invivoscribe ® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has ...

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat(R) KMT2A + MRD Assay and Software to its industry-leading ...

SAN DIEGO — Invivoscribe, a global leader in precision diagnostics, has announced the launch of an Immune Biomarker Discovery grant program, focused on supporting development, validation and ...

IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. Invivoscribe, a ...

SAN DIEGO, May 19, 2020 /PRNewswire/ -- Invivoscribe to offer the LeukoStrat ® CDx FLT3 Mutation Assay as an FDA approved kit with analysis software. In 2017, Invivoscribe's LeukoStrat ® CDx FLT3 ...

SAN DIEGO, May 12, 2020 /PRNewswire/ -- Invivoscribe is pleased to announce that their LeukoStrat ® CDx FLT3 Mutation Assay was submitted to regulatory authorities in China in April in support of the ...

SAN DIEGO--(BUSINESS WIRE)--Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat ® KMT2A + MRD Assay and Software ...

The MarketWatch News Department was not involved in the creation of this content. IdentiClone(R) Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements ...